Quantitative tracking of Cryptosporidium infection in cell culture with CFSE.

PubWeight™: 0.91‹?›

🔗 View Article (PMID 17304819)

Published in J Parasitol on December 01, 2006

Authors

Hanping Feng1, Weijia Nie, Ruben Bonilla, Giovanni Widmer, Abhineet Sheoran, Saul Tzipori

Author Affiliations

1: Division of Infectious Diseases, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA.

Articles by these authors

Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 5.64

The genome of Cryptosporidium hominis. Nature (2004) 3.93

Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98

Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg (2005) 1.90

Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89

Self-regulation of Candida albicans population size during GI colonization. PLoS Pathog (2007) 1.85

Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79

Prevalence of Enterocytozoon bieneusi in swine: an 18-month survey at a slaughterhouse in Massachusetts. Appl Environ Microbiol (2002) 1.78

Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78

Genomic survey of the non-cultivatable opportunistic human pathogen, Enterocytozoon bieneusi. PLoS Pathog (2009) 1.73

A hundred-year retrospective on cryptosporidiosis. Trends Parasitol (2008) 1.69

Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg (2003) 1.64

Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis (2010) 1.56

Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev (2004) 1.55

Enterocytozoon bieneusi among children with diarrhea attending Mulago Hospital in Uganda. Am J Trop Med Hyg (2002) 1.50

Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49

Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clin Infect Dis (2008) 1.46

Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38

Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38

Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg (2006) 1.35

An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34

The reduced genome of the parasitic microsporidian Enterocytozoon bieneusi lacks genes for core carbon metabolism. Genome Biol Evol (2010) 1.30

The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25

A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One (2012) 1.24

Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23

Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice. J Infect Dis (2002) 1.22

A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22

Identification of genotypically mixed Cryptosporidium parvum populations in humans and calves. Mol Biochem Parasitol (2003) 1.21

Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21

Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med (2011) 1.19

Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun (2008) 1.19

Differential evolution of repetitive sequences in Cryptosporidium parvum and Cryptosporidium hominis. Infect Genet Evol (2005) 1.18

Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry (2008) 1.17

Patterns of genome evolution among the microsporidian parasites Encephalitozoon cuniculi, Antonospora locustae and Enterocytozoon bieneusi. PLoS One (2007) 1.16

A pig model of the human gastrointestinal tract. Gut Microbes (2013) 1.15

Inferences about the global population structures of Cryptosporidium parvum and Cryptosporidium hominis. Appl Environ Microbiol (2008) 1.15

Emergence of distinct genotypes of Cryptosporidium parvum in structured host populations. Appl Environ Microbiol (2006) 1.13

Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun (2003) 1.12

Experimental evidence for genetic recombination in the opportunistic pathogen Cryptosporidium parvum. Mol Biochem Parasitol (2002) 1.09

Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol (2007) 1.09

UV inactivation of Cryptosporidium hominis as measured in cell culture. Appl Environ Microbiol (2005) 1.08

Characterization of RAP, a quorum sensing activator of Staphylococcus aureus. FEMS Microbiol Lett (2003) 1.06

EspFU, a type III-translocated effector of actin assembly, fosters epithelial association and late-stage intestinal colonization by E. coli O157:H7. Cell Microbiol (2007) 1.06

A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06

Detection and genotyping of oocysts of Cryptosporidium parvum by real-time PCR and melting curve analysis. J Clin Microbiol (2002) 1.05

Genetic crosses in the apicomplexan parasite Cryptosporidium parvum define recombination parameters. Mol Microbiol (2007) 1.04

Characterization of Cryptosporidium meleagridis of human origin passaged through different host species. Infect Immun (2003) 1.02

Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun (2009) 1.02

Survey and genetic characterization of wastewater in Tunisia for Cryptosporidium spp., Giardia duodenalis, Enterocytozoon bieneusi, Cyclospora cayetanensis and Eimeria spp. J Water Health (2012) 1.01

Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages. Microb Pathog (2009) 0.99

Evidence of host-associated populations of Cryptosporidium parvum in Italy. Appl Environ Microbiol (2012) 0.99

Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol (2010) 0.98

Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis (2009) 0.98

Production and characterization of monoclonal antibodies against Enterocytozoon bieneusi purified from rhesus macaques. Infect Immun (2005) 0.97

Purification of Enterocytozoon bieneusi from stools and production of specific antibodies. J Clin Microbiol (2005) 0.97

Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95

The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins. Proteomics (2009) 0.94

Rapid displacement of Cryptosporidium parvum type 1 by type 2 in mixed infections in piglets. Infect Immun (2003) 0.92

Subtype analysis of Cryptosporidium isolates from children in Uganda. J Parasitol (2006) 0.91

Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2. Infect Immun (2010) 0.91

Microsporidiosis and malnutrition in children with persistent diarrhea, Uganda. Emerg Infect Dis (2009) 0.91

Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome. Proteome Sci (2009) 0.91

Allele- and tir-independent functions of intimin in diverse animal infection models. Front Microbiol (2012) 0.91

Enhanced Actin Pedestal Formation by Enterohemorrhagic Escherichia coli O157:H7 Adapted to the Mammalian Host. Front Microbiol (2011) 0.90

Tegumental phosphodiesterase SmNPP-5 is a virulence factor for schistosomes. Infect Immun (2011) 0.90

Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens. Hum Vaccin Immunother (2012) 0.90

Monoclonal antibodies against Enterocytozoon bieneusi of human origin. Clin Diagn Lab Immunol (2005) 0.90

Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J Infect Dis (2012) 0.89

Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine (2010) 0.89

Cryptosporidium meleagridis: infectivity in healthy adult volunteers. Am J Trop Med Hyg (2011) 0.89

Serial propagation of the microsporidian Enterocytozoon bieneusi of human origin in immunocompromised rodents. Infect Immun (2006) 0.89

A comparison of the Giardia lamblia trophozoite and cyst transcriptome using microarrays. BMC Microbiol (2011) 0.88

Evidence that Cryptosporidium parvum populations are panmictic and unstructured in the Upper Midwest of the United States. Appl Environ Microbiol (2012) 0.88

Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immunother (2013) 0.87

In vivo versus in vitro protein abundance analysis of Shigella dysenteriae type 1 reveals changes in the expression of proteins involved in virulence, stress and energy metabolism. BMC Microbiol (2011) 0.86

A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1. J Infect Dis (2010) 0.86

Bile acids enhance invasiveness of Cryptosporidium spp. into cultured cells. Infect Immun (2006) 0.86

Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine (2011) 0.86